Related references
Note: Only part of the references are listed.Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Lenka Novakova et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Lenka Novakova et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis
M. Mollgaard et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis
Joachim Burman et al.
JOURNAL OF NEUROIMMUNOLOGY (2016)
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
Hlin Kvartsberg et al.
ALZHEIMERS & DEMENTIA (2015)
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease
Erik Portelius et al.
BRAIN (2015)
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
M. Alba Mane Martinez et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Jens Kuhle et al.
NEUROLOGY (2015)
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Maartje I. Kester et al.
JAMA NEUROLOGY (2015)
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
M. Alba Mane Martinez et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
Jens Kuhle et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment
Clas Malmestrom et al.
JOURNAL OF NEUROIMMUNOLOGY (2014)
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
Markus Axelsson et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis
Signe Modvig et al.
PLOS ONE (2013)
Astrocyte and Macrophage Regulation of YKL-40 Expression and Cellular Response in Neuroinflammation
Dafna Bonneh-Barkay et al.
BRAIN PATHOLOGY (2012)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Inflammation, demyelination, and degeneration - Recent insights from MS pathology
Christine Stadelmann et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
M. Axelsson et al.
JOURNAL OF NEUROLOGY (2011)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Mohsen Khademi et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis
M. M. Verbeek et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
Manuel Comabella et al.
BRAIN (2010)
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
Annika Thorsell et al.
BRAIN RESEARCH (2010)
The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases
Gregory Conductier et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Serum levels of CXCL13 are elevated in active multiple sclerosis
Eugene D. Festa et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
F. Sellebjerg et al.
NEUROLOGY (2009)
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
C. E. Teunissen et al.
NEUROLOGY (2009)
Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
RHSR Roxburgh et al.
NEUROLOGY (2005)
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
C Malmeström et al.
NEUROLOGY (2003)
The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage
T Owens
CURRENT OPINION IN NEUROLOGY (2003)
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals
F Cotton et al.
NEUROLOGY (2003)
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)
DJ Mahad et al.
SEMINARS IN IMMUNOLOGY (2003)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies
D Franciotta et al.
JOURNAL OF NEUROIMMUNOLOGY (2001)
Share Paper
